Weight gain · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state: clinically important change in mental state · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: suicidal thoughts (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: amisulpiride + needs‐focused intervention changes adverse effects: suicidal thoughts (events) compared with needs‐focused intervention (very low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group B antipsychotic drugs: amisulpiride + needs‐focused intervention changes satisfaction with treatment: leaving the study early Endpoint data… compared with needs‐focused intervention (very low certainty).
1 finding from 1 review
Volume of breast milk at the latest time measured (mL) ‐ domperidone, metoclopramide, sulpiride ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (CGI ‐ unchanged/worse) · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes global state: Average endpoint global state score (clinically… compared with sulpiride (very low certainty).
1 finding from 1 review
Adverse effects: Clinically important general adverse effect ‐ requiring hypnotics/sedatives · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect ‐… compared with sulpiride (very low certainty).
1 finding from 1 review
Death: Suicide and natural causes (no data) · schizophrenia
1 finding from 1 review
Length of hospital stay · schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Leaving the study early · schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with sulpiride (very low certainty).
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia
1 finding from 1 review
Clinical response: no clinically significant response in mental state: 20% to 50% reduction in PANSS total score · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
Weight gain · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes adverse effects: weight gain compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review